|Day Low/High||46.39 / 46.90|
|52 Wk Low/High||12.56 / 29.81|
Pfizer said Monday it has agreed to acquire Array Biopharma in an all-cash deal that values the cancer drug specialist at around $11.4 billion.
- Proposed acquisition strengthens Pfizer's innovative biopharmaceutical business and is expected to accelerate its growth trajectory particularly in the long term
Ironically, some experts now see biotech as a safe haven as the sector remains unaffected by trade wars and other global headwinds.
A roundup of Jim Cramer's thoughts on stocks of interest to Mad Money viewers.
Key oscillator signal works again, but that's no reason to nod off, Jim Cramer says.
BOULDER, Colo., June 4, 2019 /PRNewswire/ -- Array BioPharma Inc.
BOULDER, Colo., May 29, 2019 /PRNewswire/ -- Array BioPharma Inc.
- Consistent with prior readouts, BRAFTOVI + MEKTOVI demonstrates 33.6 months median overall survival with longer median follow up over 48 months -
- BRAFTOVI combinations showed statistically significant improvement in ORR and OS versus control -
BOULDER, Colo., May 9, 2019 /PRNewswire/ -- Array BioPharma Inc.
- Net product sales of BRAFTOVI® (encorafenib) + MEKTOVI® (binimetinib) in U.S. were $35.1 million in the third quarter -
BOULDER, Colo., April 30, 2019 /PRNewswire/ -- Array BioPharma Inc.
For investors interested in biotech, there's a lot to choose from, with options ranging from startups with potentially blockbuster new treatments to companies those that have been around the block a few times.
BOULDER, Colo., March 18, 2019 /PRNewswire/ -- Array BioPharma Inc.
BOULDER, Colo., March 5, 2019 /PRNewswire/ -- Array BioPharma Inc.
Experts offer their top stock ideas in oncology detection and treatment.
The cancer drugmaker post narrower-than-expected losses for the quarter and strong revenue growth.
- Strong quarter for BRAFTOVI® (encorafenib) + MEKTOVI® (binimetinib) in U.S. with $22.7 million in net product sales, which represents quarter over quarter growth of 62% -
- Data will be presented at ASCO 2019 Gastrointestinal Cancers Symposium -
BOULDER, Colo., Dec.
Investors in Array BioPharma Inc. saw new options begin trading this week, for the November 16th expiration.
Investors in Array BioPharma Inc. saw new options begin trading this week, for the March 2019 expiration.
Leading up to potential FDA approvals can be particularly 'dicey' times for biotech investors.
Investors in Array BioPharma Inc. saw new options begin trading this week, for the December 21st expiration.
TheStreet’s Fundamentals of Investing Course will teach you the keys to making the right decisions in any market.
TheStreet’s Personal Finance Essentials Course will teach you money management basics and investing strategies to help you avoid major financial pitfalls.
TheStreet Courses offers dedicated classes designed to improve your investing skills, stock market knowledge and money management capabilities.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.